IL1B and Venous thrombosis: As the Canakinumab Anti‐inflammatory Thrombosis Outcome Study [29] of 10 061 similarly overweight subjects with hsCRP > 2 mg/L has shown that treament with the IL‐1β neutralizing antibody canakinumab reduces CVD, we measured plasma IL‐1β concentrations in the overweight cohort.